Market Closed -
Japan Exchange
02:00:00 2024-04-26 am EDT
5-day change
1st Jan Change
3,585
JPY
+1.41%
+4.82%
+16.02%
Kissei Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 8, 2023, has closed with 1,909,900 shares, representing 4.18% for ¥5,999.99 million.
The company closed its plan on March 18, 2024.
Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program
Mar. 20
MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
Mar. 19
CI
Kissei Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 8, 2023, has closed with 1,909,900 shares, representing 4.18% for ¥5,999.99 million.
Mar. 17
CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024
Jan. 30
CI
Kissei Pharmaceutical Repurchases 251 Million Yen Worth of Shares in December 2023
Jan. 04
MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
Jan. 04
CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching
Dec. 12
MT
Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
Dec. 12
CI
Japanese Shares Close Lower on Tuesday After Key Economic Data
Nov. 07
MT
Kissei Pharmaceutical's Fiscal H1 Attributable Profit Surges as Net Sales Gains
Nov. 07
MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Nov. 06
CI
Kissei Pharmaceutical Co., Ltd. Announces Second Quarter-End Dividend for the Year Ending March 31, 2024, Payable on December 4, 2023 and Provided Dividend Guidance for the Year Ending March 31, 2024
Nov. 06
CI
Jefferies Downgrades Kissei Pharmaceutical to Hold From Buy, Adjusts Price Target to 3,400 Yen From 3,300 Yen
23-10-30
MT
Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023
23-10-27
CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
23-10-02
CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024
23-07-31
CI
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024
23-07-31
CI
Kissei Pharmaceutical Withdraws Marketing Approval Application for Rovatirelin
23-07-19
MT
Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan
23-07-19
CI
Kissei Pharmaceutical Co., Ltd. Introduces Iktos AI Drug Discovery System
23-07-03
CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.
23-07-03
CI
The Hachijuni Bank, Ltd. completed the acquisition of the remaining 98.33% stake in The Naganobank, Ltd. from The Master Trust Bank of Japan, Ltd. (Trust Account), Custody Bank of Japan, Ltd. (Trust Account), The Tochigi Bank, Ltd., Kissei Pharmaceutical Co., Ltd.,Sompo Japan Insurance Inc. and others.
23-05-31
CI
Kissei Pharmaceutical's Full-Year Profit Falls 18.5%
23-05-10
MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024
23-05-09
CI
Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 23, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024
23-05-09
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
More about the company
Last Close Price
3,585
JPY
Average target price
3,833
JPY
Spread / Average Target
+6.93%
Consensus
1st Jan change
Capi.
+16.02% 1.01B +5.31% 70.44B +10.97% 8.94B -16.83% 4.75B +43.48% 4.5B +3.20% 3.85B +18.82% 2.38B -21.36% 2.34B -29.67% 2.2B +8.38% 1.96B
Specialty & Advanced Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1